Multimodal Artificial Intelligence to Accelerate HIV Clinical Care (R01 Clinical Trial Optional)
ID: 358119Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $750K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358119

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-105.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Multimodal Artificial Intelligence to Accelerate HIV Clinical Care" under the R01 Research Project Grant. This initiative aims to leverage advanced multimodal AI techniques to enhance the diagnosis, prevention, and treatment of HIV, with a focus on developing unbiased AI models and knowledge graphs to improve clinical outcomes. The program encourages collaborative multidisciplinary teams to engage community stakeholders, ensuring ethical practices and data privacy while integrating at least two data modalities in their proposals. A total of $4 million will be allocated for up to six awards, with a maximum budget of $750,000 per year, and applications are due by March 28, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-MH-26-105-Full-Announcement.html
    RFA-MH-26-105.html
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is offering a funding opportunity titled "Multimodal Artificial Intelligence to Accelerate HIV Clinical Care" under the R01 Research Project Grant. This initiative aims to utilize advanced multimodal AI techniques to enhance the diagnosis, prevention, and treatment of HIV. Key objectives include developing unbiased multimodal AI models, creating knowledge graphs for better interpretability, and exploring the integration of these technologies to improve HIV care. Collaborative multidisciplinary teams are encouraged to engage community stakeholders to ensure ethical practices and data privacy. Proposals must demonstrate the integration of at least two data modalities and will be evaluated based on innovation, scientific rigor, and potential impact on HIV clinical outcomes. Two funding institutes will allocate a total of $4 million for up to six awards, with a maximum budget of $750,000 per year, and applications are due by March 28, 2025. This NOFO emphasizes the necessity of a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research, ensuring diverse representation and consideration of stakeholders’ views.
    Similar Opportunities
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at testing innovative care models that integrate HIV, addiction, and primary care services. This initiative seeks to address gaps in comprehensive health service delivery for individuals at heightened risk for HIV or living with HIV and substance use disorders, emphasizing the need for replicable and sustainable interventions. The program is critical for enhancing service delivery to vulnerable populations and aligns with national public health goals to combat the HIV epidemic in the United States. Interested applicants can apply for a share of the $2 million funding by March 20, 2025, and should direct inquiries to grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html for more details.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting R01 Clinical Trials. This initiative seeks to develop and evaluate innovative care models that effectively integrate services for HIV/AIDS, substance use disorders (SUD), and optional hepatitis, with the goal of enhancing healthcare delivery and improving health outcomes for affected individuals. The program aligns with the "Ending the HIV Epidemic: A Plan for America" initiative and emphasizes the importance of coordinated care in settings such as Federally Qualified Health Centers. Eligible applicants include various institutions and organizations, with an expected award budget of up to $2 million for fiscal year 2026 and a project duration of up to five years. Interested parties can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by March 19, 2025.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.